Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596723 · ClinicalTrials.gov registry record · Phase 3
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
A Phase 3 study, sponsored by Kala Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT03596723: Clinical Trial Phase 3 study, sponsored by Kala Pharmaceuticals.
NCT03596723 is a Phase 3 study that was terminated before completion, run by Kala Pharmaceuticals. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596723, a Phase 3 study, was terminated before completion, sponsored by Kala Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
Primary Outcome
Anterior chamber cell grading is a way of quantifying the amount of inflammation in inflammatory eye processes. Higher values indicate greater inflammation. The anterior chamber cell grading uses whole numbers from 0 (no cells) to 4 (\> 30 cells) as follows: Anterior chamber cell grade 0 = no cells seen Anterior chamber cell grade 1 = 1 - 5 cells Anterior chamber cell grade 2 = 6 - 15 cells Anterior chamber cell grade 4 = greater than 30 cells
Interventions
- DRUG Prednisolone acetate
- DRUG KPI-121 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 3 |
Why NCT03596723 stopped before completion
NCT03596723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Prednisolone acetate is the first listed.
NCT03596723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03596723 about?
NCT03596723 is a clinical study titled "KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children". This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
What is the current status of trial NCT03596723?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2018-07-03. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT03596723?
The interventions under investigation include: Prednisolone acetate (DRUG), KPI-121 1% (DRUG).
Who is sponsoring clinical trial NCT03596723?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03596723's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI